Albany, NY -- (SBWIRE) -- 03/22/2016 -- A new market study by Transparency Market Research (TMR) presents a complete overview of the global market for acute myeloid leukemia (AML) therapeutics. The research report, titled "Acute Myeloid Leukemia (AML) Therapeutics Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018," is available on the firm's website for sale.

According to the market study, the worldwide AML therapeutics market is likely to rise at a CAGR of 17.30% during the period from 2012 to 2018 and increase from a total value of US$0.2 bn in 2011 to an estimated value of US$0.7 bn by the end of the forecast period.

Although the global AML therapeutics market is exhibiting the promise of a thriving future, the past performance of this market was not very assertive, with a moderate CAGR of 2.9% exhibited by the market during the period from 2005 to 2010, states the market report.

The research report further states that the increasing prevalence of acute myeloid leukemia, stimulated by the rise in the global population, specifically the geriatric population, is fueling the demand for ALM therapeutics across the world.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=597

Apart from this, the presence of a robust therapeutic pipeline, the rising research and development activities in this field, and the introduction of novel AML drugs are also boosting the worldwide AML therapeutics market significantly.

Additionally, the global AML therapeutics market is anticipated to derive its growth from the pipeline drugs and metabolic inhibitors over the forecast period. The introduction of PKC412 by Novartis is also expected to propel the global AML therapeutics market in the coming years, states the market report.

The research study has evaluated the global market for AML therapeutics on the basis of the regional spread of this market. According to the report, North America, Europe, Asia Pacific, and the Rest of the World are the key regional markets for AML therapeutics. North America led the global market in 2010 with a share of 62% in terms of sales and was closely followed by Asia Pacific and Europe.

As per the research study, the worldwide market for AML therapeutics is highly concentrated, with a few leading players such as GlaxoSmithKline Pharmaceuticals Ltd., Novartis International AG, F. Hoffmann-La Roche AG, Bristol-Myers Squibb, and Genmab A/S accounting for a share of more than 70% in the overall market.

Clavis Pharma ASA, Ambit Biosciences Corp., Celgene Corp., Genzyme Corp., Cephalon Inc., Eisai Co. Ltd., and Sunesis Pharmaceuticals Inc. are some of the other prominent companies functioning in the global AML therapeutics market profiled in this research report.

Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/